GC
EBS icon

Gould Capital’s Emergent Biosolutions EBS Stock Holding History

Gould Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$838 Hold
100
– – ﹤0.01% 208
2026
Q1 		$830 Hold
100
– – ﹤0.01% 195
2025
Q4 		$1.24K Hold
100
– – ﹤0.01% 183
2025
Q3 		$882 Hold
100
– – ﹤0.01% 205
2025
Q2 		$638 Hold
100
– – ﹤0.01% 206
2025
Q1 		$486 Hold
100
– – ﹤0.01% 205
2024
Q4 		$956 Hold
100
– – ﹤0.01% 197
2024
Q3 		$835 Hold
100
– – ﹤0.01% 202
2024
Q2 		$682 Hold
100
– – ﹤0.01% 206
2024
Q1 		$253 Hold
100
– – ﹤0.01% 189
2023
Q4 		$240 Hold
100
– – ﹤0.01% 192
2023
Q3 		$316 Hold
100
– – ﹤0.01% 192
2023
Q2 		$735 Buy
+100
New +$927 ﹤0.01% 186

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Gould Capital's EBS Position: Q2 2026 in Review

Gould Capital held its Emergent Biosolutions (EBS) position steady in Q2 2026 at 100 shares worth $838. The position accounts for ﹤0.01% of the portfolio, ranked #208.

Gould Capital first reported a position in EBS in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.24K in Q4 2025. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Gould Capital held 100 shares of Emergent Biosolutions worth $838 as of Q2 2026.
  • Gould Capital left its Emergent Biosolutions share count unchanged in Q2 2026.
  • Emergent Biosolutions made up ﹤0.01% of Gould Capital's portfolio in Q2 2026, its #208 holding.
  • Gould Capital first reported a position in Emergent Biosolutions in Q2 2023 and has held it in 13 quarters since.
  • Gould Capital's Emergent Biosolutions position peaked at $1.24K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Gould Capital's 13F filing for Q2 2026, filed 7 Aug 2026.